News

We are proud to share a major milestone in cardiovascular innovation – the successful first-in-Russia implantation of MemoSorb biodegradable occluders for ASD (Atrial Septal Defect) and PFO (Patent Foramen Ovale).

CN&RU This landmark procedure was jointly performed by the team at Bakoulev National Medical Research Center for Cardiovascular Surgery (Russia) and leading Chinese experts. The live case was broadcasted during the All-Russian Cardiovascular Congress, demonstrating the power of international collaboration and cutting-edge technology.

Why MemoSorb stands out:

· Biodegradable framework – gradually absorbs after promoting tissue regeneration

· Stable scaffold formation during defect closure, minimizing permanent metal implants in the heart

For the global CHD community, this represents a leap forward – reducing lifetime risks associated with permanent metal devices, especially in younger patients.

Let's connect if you are interested in clinical data, partnership opportunities, or bringing biodegradable technologies to your market.